Umut DAĞ, Selahattin BALSAK

Choroidal Thickness and Serum Asymmetric Dimethylarginine Levels in Patients with Systemic Sclerosis

In addition to skin and visceral organ involvement, various ocular manifestations have also been described in patients with systemic sclerosis (SSc) or scleroderma. In recent years, optical coherence tomography (OCT) has been introduced into use as a beneficial imaging method in determining macular changes and in measuring choroidal thickness. Asymmetric dimethylarginine (ADMA) is a marker investigated in critical patients due to its proven reductive effect on nitric oxide synthesis. The present study aimed to evaluate serum ADMA levels and changes in choroidal thickness in SSc patients. The study included 20 adult SSc patients and 23 age- and sex-matched healthy subjects. Patients who had diabetes mellitus, hypertension, hypercholesterolemia, coronary heart disease, advanced-stage heart failure, renal failure, and a history of medication use and smokers and alcohol consumers were excluded. Patients’ demographic characteristics and medical histories were recorded. Choroidal thickness was measured using OCT in the right and left eyes of the patients and controls. ADMA levels were measured in the serum samples. The mean choroidal thickness was lower in the SSc group than in the control group; however, the difference reached the level of statistical significance only in nasal measurements (251.7±78.6 μm for the SSc patients and 279.2±50.7 μm for the control group; p=0.044). The ADMA level was found to be significantly higher in the SSc group than in the control group (0.545±0.130 μMol/L and 0.130±0.155 μMol/L, respectively; p=0.034). Based on the study outcomes, the serum ADMA level was significantly elevated in the SSc patients in the period when choroidal changes were not evident yet. A better understanding of the data about SSc etiopathogenesis and the role of ADMA in this process would make a contribution to the studies performed to develop new treatment strategies.

PDF

___

1. Singh D, Parihar AK, Patel S, et al. Scleroderma: An insight into causes, pathogenesis and treatment strategies. Pathophysiology 2019; 26: 103-114.
2. Ingegnoli F, Ughi N, Mihai C. Update on the epidemiology, risk factors, and disease outcomes of systemic sclerosis. Best Pract Res Clin Rheumatol 2018; 32: 223-240.
3. Kreps EO, Carton C, Cutolo M, et al. Ocular involvement in systemic sclerosis: A systematic literature review, it's not all scleroderma that meets the eye. Semin Arthritis Rheum 2019; 49: 119-125.
4. Fett N. Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies. Clin Dermatol 2013; 31: 432-437.
5. Tailor R, Gupta A, Herrick A, et al. Ocular manifestations of scleroderma. Surv Ophthalmol 2009; 54: 292-304.
6. Chan A, Duker JS, Ko TH, et al. Normal macular thickness measurements in healthy eyes using Stratus optical coherence tomography. Arch Ophthalmol 2006; 124: 193-198.
7. Brinkmann SJ, de Boer MC, Buijs N, et al. Asymmetric dimethylarginine and critical illness. Curr Opin Clin Nutr Metab Care 2014; 17: 90-97.
8. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581-590.
9. Tan KA, Gupta P, Agarwal A, et al. State of science: Choroidal thickness and systemic health. Surv Ophthalmol 2016; 61: 566-581.
10. Ingegnoli F, Gualtierotti R, Pierro L, et al. Choroidal impairment and macular thinning in patients with systemic sclerosis: the acute study. Microvasc Res 2015; 97: 31-36.
11. Coşkun E, Zengin O, Kenan S, et al. Evaluation of choroidal thickness in patients with scleroderma. Eye (Lond) 2016; 30: 588-592.
12. Esen E, Tas DA, Sizmaz S, et al. Evaluating choroidal characteristics in systemic sclerosis using enhanced depth imaging optical coherence tomography. Ocul Immunol Inflamm 2017; 25: 356-362.
13. Aydin E, Atik S, Koc F, et al. Choroidal and central foveal thickness in patients with scleroderma and its systemic associations. Clin Exp Optom 2017; 100: 656-662.
14. Dooley A, Gao B, Bradley N, et al. Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology (Oxford) 2006; 45: 676-684.
15. Németh B, Ajtay Z, Hejjel L, et al. The issue of plasma asymmetric dimethylarginine reference range - a systematic review and meta-analysis. PLoS One. 2017; 12: e0177493.
16. Wieczór AM, Wieczór R, Kulwas A, et al. Asymmetric dimethylarginine and angiogenesis: biological significance. Int Angiol 2018; 37: 431-436.
17. Zhou S, Zhu Q, Li X, et al. Asymmetric dimethylarginine and all-cause mortality: a systematic review and meta-analysis. Sci Rep 2017; 7: 44692.
18. Tain YL, Hsu CN. Toxic dimethylarginines: asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA). Toxins (Basel) 2017; 9: 92.
19. Zhang L, Wan YN, Zhao JH, Wang YJ, Wang YX, Yan JW, Huang XL, Wang J. The association between systemic sclerosis, arginine and asymmetric dimethylarginine. Inflammation 2015; 38: 218-223.
20. Blaise S, Maas R, Trocme C, et al. Correlation of biomarkers of endothelium dysfunction and matrix remodeling in patients with systemic sclerosis. J Rheumatol 2009; 36: 984-988.
21. Dağ Ş, Budulgan M, Dilek B, et al. Relation of asymmetric dimethylarginine and cardiac involvement in systemıc sclerosis. ActaReumatol Port 2014; 39: 228-235.
22. Dimitroulas T, Giannakoulas G, Sfetsios T, et al. Asymmetrical dimethylarginine in systemic sclerosis-related pulmonary arterial hypertension. Rheumatology (Oxford). 2008; 47: 1682-1685.
23. Silva I, Teixeira A, Oliveira J, et al. Endothelial dysfunction and nailfoldvideocapillaroscopy pattern as predictors of digital ulcers in systemic sclerosis: a cohort study and review of the literature. Clin Rev Allergy Immunol 2015; 49: 240-252.